Press Release October 28, 2020

Cerevel Therapeutics Debuts as Publicly Traded Neuroscience Company

The Life Sciences and SPAC teams advised Cerevel Therapeutics on the completion of its business combination with ARYA Sciences Acquisition Corp II (Nasdaq: ARYBU), a special purpose acquisition company sponsored by Perceptive Advisors, previously announced on July 30. Cerevel Therapeutics Holdings, Inc., the resulting company, will commence trading its shares under the symbol “CERE” and its warrants under the symbol “CEREW” today on the Nasdaq Capital Market. Net proceeds from this transaction totaled approximately $440 million, which included funds held in ARYA II’s trust account and the concurrent private investment in public equity financing. The shareholders of ARYA II approved the transaction on October 26. The transaction was previously approved by Cerevel Therapeutics shareholders. 

The Goodwin life sciences team was led by Stuart Cable, Arthur McGivern, James Xu, and John Mei. The Goodwin SPAC team was led by Jocelyn Arel and Dan Espinoza.

For additional details on the completion of the transaction, please read the press release